EGFR and neoplasm: To overcome the limitations of tissue-based EGFR CDx, peripheral blood-based surrogate markers, such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs), have emerged as promising alternatives for EGFR mutation assessment [18].